Deal of the Week Regeneron will pay Tessera Pharmaceuticals $150 million upfront as part of a gene-editing partnership for a rare liver and lung disease, known as alpha-1 antitrypsin deficiency
Topical Treatment for Acute Phase Peyronies Disease Utilizing a New Gel, H-100: A Randomized, Prospective, Placebo-Controlled Pilot Study
10.1371/journal.pcbi.1004137 PLoS Comput
consult a healthcare professional if concerned
3.2 Arrhythmia analysis Separate data-analyses were estimated according to the type of adverse event arrhythmia disclosed, homogeneity of included studies was good for all events, with the following results:atrial fibrillation ( I 2 = 44%, p =0.08), atrial flutter ( I 2 = 0%, p =0.49), ventricular fibrillation ( I 2 = 0%, p =0.86), ventricular tachycardia ( I 2 = 0%, p =0.42), atrial tachycardia ( I 2 = 0%, p =0.45), sinus node ( I 2 = 0%, p =0.54), ventricular precontraction ( I 2 = 0%, p =0.64), second degree AV block ( I 2 = 0%, p =0.84), and complete AV block ( I 2 = 40%, p =0.13), so a fixed-effect model was used to combine effect sizes